World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
All Topics Article
Key FDA Approval Yanked for Avastin
Keywords:
Tags: Pharmaceutical,
Genentech's Lucentis and Avastin eye treatments
04/28/2011
Avastin eye treatment at $50 per treatment is significantly cheaper than the Lucentis eye treatment. Lucentis is also made by Genentech.
Grouped Articles
Genentech Fights the Use of Its Own Cheaper Drug
Wall Street Journal 04/28/2011
Clinical Trial Says Avastin as Effective as Lucentis for Macular Degeneration
New York Times 04/28/2011
Showdown Over Use of Cancer-Drug Avastin
Wall Street Journal 06/27/2011
Key FDA Approval Yanked for Avastin
Wall Street Journal 11/19/2011
Genentech
06/05/2007
Genentech before and after the complete acquisition of Genentech by Roche in 2008.
Grouped Articles
How Genentech Wins At Blockbuster Drugs
Wall Street Journal 06/05/2007
Can Genentech Stage a Recovery?
Wall Street Journal 07/23/2007
BusinessWeek 12/05/2007
Pricey Drugs Put Squeeze on Doctors
Wall Street Journal 07/08/2008
Roche Offers to Buy Full Stake in Genentech
Wall Street Journal 07/22/2008
Roche Bid Blindsided Genentech
Wall Street Journal 07/22/2008
The FDA and Genentech's breast cancer drug Avastin
01/07/2011
Grouped Articles
Regulator Defends Avastin Decision
Wall Street Journal 01/07/2011
Resistance to FDA on Avastin Limits
Wall Street Journal 04/08/2011
Showdown Over Use of Cancer-Drug Avastin
Wall Street Journal 06/27/2011
Key FDA Approval Yanked for Avastin
Wall Street Journal 11/19/2011
Genentech Wins Approval For New Breast Cancer Drug
New York Times 06/08/2012
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us